Mechanistically, transferrin directly interacts with TRAC with a high affinity of 10.9 nM (Fig. 3A to C) to interfere with TCR–CD3 complex interaction to suppress TCR activation and anti-tumor immunity, while blocking transferrin–TRAC interaction inhibited metastasis and showed significant anti-tumor effects. Here, TRAC is linked to neoplasm.